HRP20200721T1 - Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe - Google Patents

Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe Download PDF

Info

Publication number
HRP20200721T1
HRP20200721T1 HRP20200721TT HRP20200721T HRP20200721T1 HR P20200721 T1 HRP20200721 T1 HR P20200721T1 HR P20200721T T HRP20200721T T HR P20200721TT HR P20200721 T HRP20200721 T HR P20200721T HR P20200721 T1 HRP20200721 T1 HR P20200721T1
Authority
HR
Croatia
Prior art keywords
cancer
activating antibody
amino acid
seq
acid sequence
Prior art date
Application number
HRP20200721TT
Other languages
English (en)
Croatian (hr)
Inventor
James William WEST
Jason Gary SAGERT
Jonathan Alexander Terrett
Annie Yang Weaver
Luc Roland DESNOYERS
Shweta SINGH
Original Assignee
Cytomx Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc. filed Critical Cytomx Therapeutics Inc.
Publication of HRP20200721T1 publication Critical patent/HRP20200721T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HRP20200721TT 2015-05-04 2016-05-04 Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe HRP20200721T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562156835P 2015-05-04 2015-05-04
US201562220805P 2015-09-18 2015-09-18
PCT/US2016/030785 WO2016179285A1 (en) 2015-05-04 2016-05-04 Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
EP16722502.8A EP3292150B1 (en) 2015-05-04 2016-05-04 Activatable anti-cd166 antibodies, and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20200721T1 true HRP20200721T1 (hr) 2020-10-02

Family

ID=55967468

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200721TT HRP20200721T1 (hr) 2015-05-04 2016-05-04 Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe

Country Status (20)

Country Link
US (3) US10745481B2 (enExample)
EP (2) EP3708585A1 (enExample)
JP (2) JP7028648B2 (enExample)
KR (1) KR20180010203A (enExample)
CN (2) CN115340607A (enExample)
AU (1) AU2016257929B2 (enExample)
BR (1) BR112017023872A2 (enExample)
CA (1) CA2984948A1 (enExample)
DK (1) DK3292150T3 (enExample)
EA (1) EA201792414A1 (enExample)
ES (1) ES2796698T3 (enExample)
HR (1) HRP20200721T1 (enExample)
HU (1) HUE049866T2 (enExample)
IL (2) IL292798A (enExample)
MX (2) MX388350B (enExample)
PL (1) PL3292150T3 (enExample)
PT (1) PT3292150T (enExample)
RS (1) RS60222B1 (enExample)
SG (2) SG10202110908WA (enExample)
WO (1) WO2016179285A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11089959B2 (en) 2013-03-15 2021-08-17 I2Dx, Inc. Electronic delivery of information in personalized medicine
US9782075B2 (en) 2013-03-15 2017-10-10 I2Dx, Inc. Electronic delivery of information in personalized medicine
IL291329B1 (en) 2013-09-25 2025-09-01 Cytomx Therapeutics Inc Polypeptides that can be determined in matrix metalloproteinases and uses thereof
CN106459153B (zh) 2014-01-31 2021-12-21 西托姆克斯治疗公司 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
AU2016257929B2 (en) 2015-05-04 2022-10-20 Cytomx Therapeutics, Inc Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
CA3039316A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
CN110177875B (zh) 2016-11-28 2023-11-28 中外制药株式会社 包含抗原结合结构域和运送部分的多肽
CN110036034A (zh) 2016-12-09 2019-07-19 西雅图遗传学公司 卷曲螺旋掩蔽的二价抗体
US11220544B2 (en) 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US11623965B2 (en) 2017-08-16 2023-04-11 Bristol-Myers Squibb Company Prodruggable antibodies, prodrugs thereof, and methods of use and making
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
MX2020002198A (es) * 2017-08-30 2020-07-20 Cytomx Therapeutics Inc Anticuerpos anti-cd166 activables y métodos de uso de los mismos.
MX2020002667A (es) 2017-09-08 2020-08-03 Maverick Therapeutics Inc Proteinas de unión condicionalmente activadas restringidas.
CN111315773A (zh) * 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
WO2019107384A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
BR112020010450A2 (pt) 2017-11-28 2020-11-24 Chugai Seiyaku Kabushiki Kaisha polipeptídeo que inclui domínio de ligação a antígeno e seção transportadora
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
EP3769309A1 (en) 2018-03-20 2021-01-27 Cytomx Therapeutics Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
MX2020012252A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
EP3816182A4 (en) 2018-05-30 2022-07-13 Chugai Seiyaku Kabushiki Kaisha LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
MX2021005116A (es) * 2018-11-02 2021-07-15 Cytomx Therapeutics Inc Anticuerpos activables anti-cd166 y metodos de uso de estos.
CA3120327A1 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
JP7695698B2 (ja) * 2019-01-14 2025-06-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞内部移行をモジュレートするための組成物および方法
WO2020176672A1 (en) * 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
CN120484127A (zh) 2019-03-05 2025-08-15 武田药品工业有限公司 受约束的条件性活化的结合蛋白
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2020191306A1 (en) 2019-03-21 2020-09-24 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
KR102212149B1 (ko) * 2019-03-28 2021-02-04 부산대학교 산학협력단 암 줄기세포에 특이적으로 결합하는 압타머 및 이의 용도
IL286846B2 (en) 2019-04-26 2025-06-01 Immunogen Inc Camptothecin derivatives
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
WO2020236679A1 (en) * 2019-05-17 2020-11-26 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
KR20220017430A (ko) 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 항체 절단 부위 결합 분자
WO2020251878A1 (en) 2019-06-11 2020-12-17 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
WO2021061867A1 (en) * 2019-09-23 2021-04-01 Cytomx Therapeutics, Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
WO2021097376A1 (en) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
KR20220166814A (ko) 2020-04-09 2022-12-19 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 항체를 함유하는 조성물
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
AU2021379015A1 (en) * 2020-11-16 2023-06-22 The Cleveland Clinic Foundation Anti-cd6 antibody conjugates for treating t-cell and b-cell mediated disorders, and t-cell and b-cell cancers
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
AU2022367525A1 (en) 2021-10-15 2024-05-02 Amgen Inc. Activatable polypeptide complex
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023086897A1 (en) * 2021-11-12 2023-05-19 University Of Florida Research Foundation, Incorporated Siglec-6 antibodies, derivative compounds and related uses
CN114621348B (zh) * 2022-01-24 2023-09-22 深圳市乐土生物医药有限公司 一种多肽及其抗磷脂酰肌醇蛋白聚糖3抗体
WO2023183888A1 (en) 2022-03-23 2023-09-28 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
EP4499685A1 (en) 2022-03-25 2025-02-05 CytomX Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
EP4504257A1 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
JP2025511187A (ja) 2022-04-01 2025-04-15 サイトムエックス セラピューティクス，インク． Ｃｄ３結合タンパク質及びその使用方法
KR20250011922A (ko) 2022-05-16 2025-01-22 비온디스 비.브이. 신규한 차폐된 항체
CN119630428A (zh) 2022-07-12 2025-03-14 西托姆克斯治疗公司 Epcam免疫缀合物及其用途
AR130079A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
WO2024030858A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
EP4565690A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030850A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
AR130076A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN120936384A (zh) 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2024216194A1 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
KR20250034273A (ko) * 2023-08-28 2025-03-11 파로스젠 주식회사 항-도펠 항체-약물 접합체
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1988001513A1 (fr) 1986-08-28 1988-03-10 Teijin Limited Complexe d'anticorps cytocide et procede de production
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
WO1999011287A1 (en) 1997-09-04 1999-03-11 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
AU9399501A (en) 2000-10-09 2002-04-22 Isis Innovation Therapeutic antibodies
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
CA2483912A1 (en) 2002-05-03 2003-11-13 Raven Biotechnologies, Inc. Alcam and alcam modulators
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
CA2549956C (en) 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
CN101253198A (zh) 2005-08-29 2008-08-27 独立行政法人科学技术振兴机构 使用鸵鸟产生的抗体及其制备方法
AU2006284651C1 (en) 2005-08-31 2013-09-12 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
US7582441B1 (en) 2005-10-17 2009-09-01 Celera Corporation Methods and compositions for treating and diagnosing disease
US8003762B2 (en) 2005-11-29 2011-08-23 Japan Science And Technology Agency Monoclonal antibody to CD166 and method for production thereof
CA2645347A1 (en) 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
GB0705775D0 (en) * 2007-03-26 2007-05-02 Affitech As Product
JP2009055899A (ja) 2007-08-07 2009-03-19 Igaku Seibutsugaku Kenkyusho:Kk Ａｄｃｃ活性を増強させた抗体及びその製造方法
EP3492488A1 (en) 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
EP2348052A3 (en) * 2007-09-17 2011-10-26 The Regents of The University of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
KR20100117120A (ko) 2008-02-20 2010-11-02 지투 인플레메이션 피티와이 엘티디 인간화된 항-Ｃ5ａＲ 항체
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
US8846870B2 (en) 2008-12-22 2014-09-30 Chugai Seiyaku Kabushiki Kaisha Anti-HS6ST2 antibodies and uses thereof
WO2010081173A2 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
CA2816681A1 (en) 2010-11-03 2012-05-10 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
AU2012253373A1 (en) * 2011-05-11 2013-11-28 Nanovalent Pharmaceuticals, Inc. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor
ES2812849T3 (es) * 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
AU2013251310B2 (en) * 2012-04-27 2018-02-15 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
EP2934575A2 (en) 2012-12-19 2015-10-28 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
CN112162094A (zh) 2013-01-04 2021-01-01 西托姆克斯治疗公司 用于检测生物系统中的蛋白酶活性的组合物和方法
US9999680B2 (en) 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
EP3003387A1 (en) * 2013-06-04 2016-04-13 Cytomx Therapeutics Inc. Compositions and methods for conjugating activatable antibodies
CA2918795A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
AU2016257929B2 (en) 2015-05-04 2022-10-20 Cytomx Therapeutics, Inc Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
EP3325006A4 (en) 2015-07-17 2019-03-06 The Trustees of Columbia University in the City of New York METHOD FOR TREATING CD166-EXPRESSIVE CANCER
CN108473961B (zh) 2015-11-04 2022-11-29 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
CN109311992B (zh) 2016-06-15 2022-10-18 克利夫兰临床基金会 用于治疗t细胞介导疾病的新型抗cd6抗体
JP6183523B2 (ja) 2016-09-14 2017-08-23 株式会社アンセイ 車両用開閉体の開閉装置及び車両用開閉体の開閉装置用リンク機構
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
WO2018071058A1 (en) 2016-10-15 2018-04-19 Baylor College Of Medicine Platform for enhanced targeted cell delivery
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
US11220544B2 (en) 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
MX2020002198A (es) 2017-08-30 2020-07-20 Cytomx Therapeutics Inc Anticuerpos anti-cd166 activables y métodos de uso de los mismos.
MX2021005116A (es) 2018-11-02 2021-07-15 Cytomx Therapeutics Inc Anticuerpos activables anti-cd166 y metodos de uso de estos.
WO2020176672A1 (en) 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies

Also Published As

Publication number Publication date
IL255414A0 (en) 2017-12-31
US20240076374A1 (en) 2024-03-07
CN115340607A (zh) 2022-11-15
EP3292150B1 (en) 2020-02-05
EA201792414A1 (ru) 2018-06-29
CN107849133B (zh) 2022-08-23
EP3708585A1 (en) 2020-09-16
ES2796698T3 (es) 2020-11-30
CA2984948A1 (en) 2016-11-10
AU2016257929A1 (en) 2017-11-30
EP3292150A1 (en) 2018-03-14
SG10201913767VA (en) 2020-03-30
PT3292150T (pt) 2020-06-01
HK1250036A1 (en) 2018-11-23
US11753466B2 (en) 2023-09-12
KR20180010203A (ko) 2018-01-30
BR112017023872A2 (pt) 2018-07-24
MX2017014136A (es) 2018-07-06
IL255414B (en) 2022-06-01
RS60222B1 (sr) 2020-06-30
WO2016179285A1 (en) 2016-11-10
CN107849133A (zh) 2018-03-27
JP2022065115A (ja) 2022-04-26
PL3292150T3 (pl) 2020-07-13
SG10202110908WA (en) 2021-11-29
JP2018520091A (ja) 2018-07-26
HUE049866T2 (hu) 2020-11-30
JP7028648B2 (ja) 2022-03-02
MX388350B (es) 2025-03-19
US20200291113A1 (en) 2020-09-17
IL292798A (en) 2022-07-01
MX2021014735A (es) 2022-01-18
DK3292150T3 (da) 2020-04-27
AU2016257929B2 (en) 2022-10-20
US20160355587A1 (en) 2016-12-08
US10745481B2 (en) 2020-08-18

Similar Documents

Publication Publication Date Title
HRP20200721T1 (hr) Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe
HRP20220172T1 (hr) Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe
JP2018520092A5 (enExample)
CN115279417B (zh) 生物活性物偶联物及其制备方法和用途
JP2018520091A5 (enExample)
JP2018520991A5 (enExample)
US20210322561A1 (en) Binding protein drug conjugates comprising anthracycline derivatives
CN111133002B (zh) 具有高体内耐受性的基于蒽环类药的抗体药物缀合物
ME02919B (me) Konjugati humanog antitijela sa lijekom protiv tkivnog faktora
HRP20231609T1 (hr) Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2
JP2015510761A5 (enExample)
CN113784987B (zh) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
JP2020500016A5 (enExample)
HRP20220631T1 (hr) Supstrati koje mogu cijepati matrične metaloproteaze i serinske proteaze, te postupci njihove uporabe
JP2017522871A5 (enExample)
JP2017509594A5 (enExample)
FI3930847T3 (fi) Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä
JP2020526584A5 (enExample)
CN112020519A (zh) 抗her2双互补位抗体-药物偶联物及使用方法
JP7264831B2 (ja) 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用
JPWO2020086665A5 (enExample)
AU2018285523A1 (en) Antibody drug conjugates that bind LGR5
CN116036303A (zh) 一种抗体-药物偶联物及其制备方法和应用
JPWO2023083846A5 (enExample)
Zhang et al. A coiled coil-based pre-targeting drug delivery system for precise treatment of breast cancer